Description

This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.

Faculty

• Aleksander Krag (Moderator)
• Naim Alkhouri (Faculty)
• Sven Francque (Faculty)
• Amalia Gastaldelli (Faculty)

Related episodes

• Season 5 , Episode 2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways
• EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
• Season 4, Episode 23: The Conundrum of NASH: The Growing Global Disease Burden with Low Disease Awareness
• Season 4, Episode 22: JHEP Live: New and promising drugs for NASH on the horizon

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Join us for a critical discussion on the significance of Drug and Herbal & Dietary Supplement-Induced Liver Injury (DHILI). In this episode, the speakers explore the importance of DHILI, assess recent advancements, and deliberate on the obstacles hindering further progress in addressing this pressing healthcare concern.

This episode is organised in collaboration with the EASL DHILI Consortium.

Faculty

• Guruprasad Padur Aithal (Moderator)
• Paul Hayashi (Faculty)
• Maribel Lucena (Faculty)
• Paul Watkins (Faculty)

Related episodes

• Season 4, Episode 20 – COST Actions: opportunities for pan-European collaborations in liver diseases

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Although there is an almost unanimous consensus on the prognostic weight of the term ‘decompensation’, a clear corresponding consensus on its definition is still lacking. In addition, classifying cirrhosis as compensated and decompensated oversimplifies the clinical course of the disease which encompasses many different groups.

Faculty

• Prof. Paolo Angeli (Moderator)
• Prof. Guadalupe Garcia-Tsao (Faculty)
• Prof. Salvatore Piano (Faculty)
• Prof. Thomas Reiberger (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

The Baveno Consensus started over 30 years ago with the aim of reviewing current diagnostic and therapeutic strategies and producing updated definitions.

But, with the extension of indication of non-steroidal beta blockers, has the consensus gone too far?

• Is there enough evidence for their use in already decompensated patients?
• How safe are they in this patient population?
• What do we know about the effects on refractory ascites? Circulatory dysfunction?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In this episode, experts explore the shift away from invasive measurements in assessing clinically significant portal hypertension. The speakers address the crucial data needed to enhance the reliability and applicability of these non-invasive methods and introduce several advanced elastography techniques, shaping the future of portal hypertension assessment.

Faculty

• Bogdan Procopet (Moderator)
• Maria Papp (Faculty)
• Atoosa Rabiee (Faculty)
• Thomas Reiberger (Faculty)

Related episode

• EASL Studio S2E14: Elastography – The new non-invasive gold standard in portal hypertension?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.